Vaxcyte Q1 net loss $320.6M; OPUS Phase 3 enrollment completed; topline data Q4 2026

Vaxcyte, Inc.

2026-Q1 EPS reported -$2.30

Cash $2.74B as of Mar 31, up from $2.44B Dec 31; includes $601.8M from Feb 2026 equity offering.
Net loss $320.6M for Q1 2026 vs $140.7M in Q1 2025; R&D expenses doubled to $312.8M.
All three VAX-31 adult Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) fully enrolled with 6,191 adults dosed.
Topline OPUS-1 data expected Q4 2026; OPUS-2 and OPUS-3 data expected H1 2027.
VAX-31 infant Phase 2 fully enrolled (900 infants); topline data by end of H1 2027; VAX-A1 Phase 1 start mid-2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vaxcyte, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 6, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0001649094-26-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.